Brief: Natera Inc Says IMvigor011 Trial Achieves 41% Improvement In Overall Survival
20/10/2025 07:50
Oct 20 (Reuters) - Natera Inc NTRA.O: NATERA INC: SUCCESSFUL IMVIGOR011 TRIAL ACHIEVES 41% IMPROVEMENT IN OVERALL SURVIVAL FOR BLADDER CANCER PATIENTS Source text: ID:nBw4YBwn4a Further company coverage: NTRA.O ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers